Renaissance Technologies LLC bought a new position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 29,100 shares of the company's stock, valued at approximately $404,000. Renaissance Technologies LLC owned 0.06% of Tyra Biosciences at the end of the most recent quarter.
Other large investors have also made changes to their positions in the company. KLP Kapitalforvaltning AS acquired a new position in Tyra Biosciences in the fourth quarter valued at about $31,000. US Bancorp DE acquired a new stake in shares of Tyra Biosciences during the fourth quarter worth $50,000. Wells Fargo & Company MN lifted its position in Tyra Biosciences by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 9,493 shares of the company's stock valued at $132,000 after acquiring an additional 3,236 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in Tyra Biosciences by 130,587.5% during the 4th quarter. Russell Investments Group Ltd. now owns 10,455 shares of the company's stock worth $145,000 after purchasing an additional 10,447 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Tyra Biosciences in the fourth quarter valued at about $149,000. Institutional investors own 84.14% of the company's stock.
Wall Street Analysts Forecast Growth
TYRA has been the subject of several research reports. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price target on shares of Tyra Biosciences in a research note on Monday, March 31st. Wedbush restated an "outperform" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a report on Friday, March 28th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tyra Biosciences has a consensus rating of "Buy" and an average target price of $30.83.
View Our Latest Analysis on Tyra Biosciences
Tyra Biosciences Trading Up 2.5 %
Tyra Biosciences stock traded up $0.25 during trading hours on Friday, reaching $10.32. 148,432 shares of the stock were exchanged, compared to its average volume of 257,435. Tyra Biosciences, Inc. has a twelve month low of $6.42 and a twelve month high of $29.60. The stock has a 50 day moving average of $9.66 and a two-hundred day moving average of $13.43. The company has a market cap of $547.89 million, a P/E ratio of -6.41 and a beta of 1.17.
Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.02. On average, analysts expect that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.
Tyra Biosciences Company Profile
(
Free Report)
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Read More

Before you consider Tyra Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.
While Tyra Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.